Vaxcyte, Inc. PCVX Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s stock issuance proceeds?
- Vaxcyte, Inc. (PCVX) reported stock issuance proceeds of $9.03M in Q1 2026.
- How has Vaxcyte, Inc.'s stock issuance proceeds changed year-over-year?
- Vaxcyte, Inc.'s stock issuance proceeds increased by 49.3% year-over-year, from $6.05M to $9.03M.
- What is the long-term trend for Vaxcyte, Inc.'s stock issuance proceeds?
- Over 3 years (2021 to 2025), Vaxcyte, Inc.'s stock issuance proceeds has grown at a -2.2% compound annual growth rate (CAGR), from $13.9M to $13.01M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.